Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Aquestive Therapeutics, Inc. Director's Dealing 2020

Apr 2, 2020

32552_dirs_2020-04-02_becfb803-84ab-4ca0-925f-3e857284e8a7.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aquestive Therapeutics, Inc. (AQST)
CIK: 0001398733
Period of Report: 2020-03-31

Reporting Person: Schobel Alexander Mark (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-03-31 Common Stock M 329 Acquired 1062210 Direct
2020-03-31 Common Stock F 97 $2.19 Disposed 1062113 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-03-31 Restricted Stock Units $0 M 329 Disposed Common Stock (329) Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F2: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability.

F3: There are no expiration dates on RSUs.